The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Accudenz     N,N'-bis(2,3- dihydroxypropyl)-5-(2...

Synonyms: iomeprol, Iomeprolo, Iomeron, Imeron, Iomeprolum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Iomeprolo


High impact information on Iomeprolo


Chemical compound and disease context of Iomeprolo


Biological context of Iomeprolo


Anatomical context of Iomeprolo


Associations of Iomeprolo with other chemical compounds

  • Nonionic contrast media iohexol and iomeprol decrease renal arterial tone: comparative studies on human and porcine isolated vascular segments [19].
  • RESULTS: Iomeprol, like ioversol, principally exerted a mild inhibitory effect on CNS synaptic transmission, an effect that was preceded by a weak, transient excitation [13].
  • RATIONALE AND OBJECTIVES: To evaluate the safety and pharmacokinetics of BR21, a liposome-encapsulated iomeprol formulation, in nonpatient volunteers [20].
  • Based on a data compilation from the literature, the lipid lowering agent metabolite clofibric acid, the iodinated X-ray contrast media iomeprol, which contribute to the adsorbable organic halogen compounds, and the antiepileptic drug carbamazepine were selected [21].
  • Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers [22].

Gene context of Iomeprolo

  • RESULTS: In all CAPD patients, plasma iomeprol clearance was markedly slow, with a biological half-life (T1/2) of over 32 hours [23].

Analytical, diagnostic and therapeutic context of Iomeprolo

  • RESULTS: The frequency of reocclusions necessitating repeat angioplasty occurring either in laboratory (2.9% with iomeprol and 3.0% with ioxaglate) or out of laboratory (3.1% vs 4.1%) was not significantly different [1].
  • In the iomeprol group, more patients had dissections post-PTCA (30.2% vs 25.0%, p = 0.01) and more patients received intracoronary stents (31.6% vs 25.7%, p = 0.004) [1].
  • Iomeprol (containing 150 to 400 mg/ml of iodine) was well tolerated in clinical trials [24].
  • Iomeprol, like others in its class, is suitable for use in diagnostic imaging [24].
  • CONCLUSIONS: Iomeprol is safe and effective and can be recommended for myelography and myelo-CT [16].


  1. A randomized trial comparing the impact of a nonionic (Iomeprol) versus an ionic (Ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty. Schräder, R., Esch, I., Ensslen, R., Fach, W.A., Merle, H., Scherer, D., Sievert, H., Spies, H.F., Zeplin, H.E. J. Am. Coll. Cardiol. (1999) [Pubmed]
  2. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Lorusso, V., Taroni, P., Alvino, S., Spinazzi, A. Investigative radiology. (2001) [Pubmed]
  3. Bacterial contamination of multiple-dose vials: a prevalence study. Mattner, F., Gastmeier, P. American journal of infection control. (2004) [Pubmed]
  4. Comparison of effects of ioxaglate versus iomeprol on histamine and tryptase release in patients with ischemic cardiomyopathy. Rodriguez, R.M., Guéant, J.L., Gastin, I.A., Angioi, M., Abdelmoutaleb, I., Saint-Laudy, J., Gérard, P., Namour, F., Grentzinger, A., Romano, A., Juillière, Y., Danchin, N. Am. J. Cardiol. (2001) [Pubmed]
  5. Clinical utility and safety profile of iomeprol. Rosati, G. European journal of radiology. (1994) [Pubmed]
  6. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Heinrich, M.C., Kuhlmann, M.K., Kohlbacher, S., Scheer, M., Grgic, A., Heckmann, M.B., Uder, M. Radiology (2007) [Pubmed]
  7. Pseudoparaproteinemia Related to Iomeprol Administration after Angiocardiography: Detection in the {beta} Fraction by Capillary Zone Electrophoresis. Vermeersch, P., Mari??n, G., Bossuyt, X. Clin. Chem. (2006) [Pubmed]
  8. Irradiation in presence of iodinated contrast agent results in radiosensitization of endothelial cells: consequences for computed tomography therapy. Joubert, A., Biston, M.C., Boudou, C., Ravanat, J.L., Brochard, T., Charvet, A.M., Estève, F., Balosso, J., Foray, N. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  9. High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: iopromide 370 versus iomeprol 400. Cademartiri, F., de Monye, C., Pugliese, F., Mollet, N.R., Runza, G., van der Lugt, A., Midiri, M., de Feyter, P.J., Lagalla, R., Krestin, G.P. Investigative radiology. (2006) [Pubmed]
  10. Analysis of iodinated X-ray contrast agents in water samples by ion chromatography and inductively-coupled plasma mass spectrometry. Sacher, F., Raue, B., Brauch, H.J. Journal of chromatography. A. (2005) [Pubmed]
  11. A prospective randomised controlled trial to determine the early and late reactions after the use of iopamidol 340 (Niopamtrade mark) and iomeprol 350 (Iomeron((R))) in cardiac catheterisation. Vijayalakshmi, K., Kunadian, B., Wright, R.A., Hall, J.A., Stewart, M.J., Davies, A., Sutton, A., de Belder, M.A. European journal of radiology (2007) [Pubmed]
  12. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Frank, H., Werner, D., Lorusso, V., Klinghammer, L., Daniel, W.G., Kunzendorf, U., Ludwig, J. Clin. Nephrol. (2003) [Pubmed]
  13. Effect of iomeprol on rat hippocampal slice synaptic transmission: comparison with other X-ray contrast agents. Frigeni, V., Samuelli, G., Miragoli, L., Grotti, A., Lorusso, V. Investigative radiology. (2002) [Pubmed]
  14. Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Peer, A., Averbukh, Z., Berman, S., Modai, D., Averbukh, M., Weissgarten, J. Investigative radiology. (2003) [Pubmed]
  15. Pharmacodynamic effects of iomeprol for injection in experimental animals. Cipolla, P., Tirone, P., Luzzani, F., de Haën, C. European journal of radiology. (1994) [Pubmed]
  16. Clinical experience with iomeprol in myelography and myelo-CT: clinical pharmacology and double-blind comparisons with iopamidol, iohexol, and iotrolan. Katayama, H., Heneine, N., van Gessel, R., Taroni, P., Spinazzi, A. Investigative radiology. (2001) [Pubmed]
  17. The nonionic radiocontrast medium iopromide does not release endothelin-1 or activate cardiac mast cells during coronary angiography. Simon, M.R., Reher, R.L., Long, P.M., Yellayi, K. Int. Arch. Allergy Immunol. (2003) [Pubmed]
  18. Influence of intracoronary attenuation on coronary plaque measurements using multislice computed tomography: observations in an ex vivo model of coronary computed tomography angiography. Cademartiri, F., Mollet, N.R., Runza, G., Bruining, N., Hamers, R., Somers, P., Knaapen, M., Verheye, S., Midiri, M., Krestin, G.P., de Feyter, P.J. European radiology. (2005) [Pubmed]
  19. Nonionic contrast media iohexol and iomeprol decrease renal arterial tone: comparative studies on human and porcine isolated vascular segments. Uder, M., Humke, U., Pahl, M., Jansen, A., Utz, J., Kramann, B. Investigative radiology. (2002) [Pubmed]
  20. Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers. Spinazzi, A., Ceriati, S., Pianezzola, P., Lorusso, V., Luzzani, F., Fouillet, X., Alvino, S., Rummeny, E.J. Investigative radiology. (2000) [Pubmed]
  21. Fate of pharmaceuticals--photodegradation by simulated solar UV-light. Doll, T.E., Frimmel, F.H. Chemosphere (2003) [Pubmed]
  22. Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers. Manke, C., Marcus, C., Page, A., Puey, J., Batakis, O., Fog, A. Acta radiologica (Stockholm, Sweden : 1987) (2003) [Pubmed]
  23. Elimination of iomeprol in patients undergoing continuous ambulatory peritoneal dialysis. Iwamoto, M., Hiroshige, K., Suda, T., Ohta, T., Ohtani, A., Nakashima, Y. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. (1999) [Pubmed]
  24. Iomeprol: a review of its use as a contrast medium. Dooley, M., Jarvis, B. Drugs (2000) [Pubmed]
WikiGenes - Universities